Diligence memo · auto-generated · as of July 2, 2026
Retension Pharmaceuticals, Inc.
Retension Pharmaceuticals, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Retension Pharmaceuticals, Inc. operates in Pharmaceuticals, based in MCLEAN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Retension Pharmaceuticals, Inc. has raised $22M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $12M on 2025-04-22.
Most recent recorded round closed around 2025-04-22.
Valuation (modeled)modeled
Provath models Retension Pharmaceuticals, Inc. at approximately $44M (range $14M–$79M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.73× the median modeled value of Series A Pharmaceuticals companies in 2025–2027 (37 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 9 months.
Last raise 14 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 2.1× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 68% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 41% of those peers.
Closest niche peers: Incannex Healthcare Inc., Eikonoklastes Therapeutics, Inc., Phoenicis Therapeutics, Inc., Pharmaceutical Resource Technology, Inc., Cristcot LLC.
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.